Financial Performance - Klotho Neurosciences, Inc. reported no revenue for the nine months ended September 30, 2024, and September 30, 2023[125]. - Operating expenses for the three months ended September 30, 2024, were $2,870,932, an increase of $2,747,195 compared to $123,737 for the same period in 2023[126]. - The net loss for the three months ended September 30, 2024, was $2,959,426, compared to a net loss of $144,111 for the same period in 2023, reflecting an increase of $2,815,315[128]. Cash Flow - As of September 30, 2024, the company had cash of $50,895 and an accumulated deficit of approximately $8.5 million[136]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $2,002,358, an increase of approximately $1,755,000 compared to $247,406 for the same period in 2023[132]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was $2,173,942, compared to $250,000 for the same period in 2023[134]. - The company expects net cash used in operating activities to increase in the coming periods until its products generate meaningful revenue[132]. Going Concern - Klotho Neurosciences, Inc. has incurred significant operating losses and negative cash flows from operations since inception, raising concerns about its ability to continue as a going concern[136]. - The company has no off-balance sheet arrangements as of September 30, 2024[137]. Company Classification - Klotho is classified as an "emerging growth company" and intends to take advantage of certain exemptions from reporting requirements[139].
Klotho Neurosciences, Inc.(KLTO) - 2024 Q3 - Quarterly Report